Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials

Background. Until recently, the approved treatment regimens for patients with hepatitis C virus (HCV) genotypes (GTs) 2 and 3 contain sofosbuvir (SOF) and ribavirin (RBV) for 12 or 24 weeks. The impact of RBV-free pan-genotypic regimen with SOF and velpatasvir (SOF/VEL) on patient-reported outcomes...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Infect Dis
Autors principals: Younossi, Zobair M., Stepanova, Maria, Sulkowski, Mark, Foster, Graham R., Reau, Nancy, Mangia, Alessandra, Patel, Keyur, Bräu, Norbert, Roberts, Stuart K., Afdhal, Nezam, Nader, Fatema, Henry, Linda, Hunt, Sharon
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Articles and Commentaries
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6276885/
https://ncbi.nlm.nih.gov/pubmed/27444413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciw496
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars